Advertisement

Topics

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

2014-08-27 03:35:47 | BioPortfolio

Summary

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy.

Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.

Description

see above

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Immunotherapy

Intervention

specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)

Location

Goethe University, Department of Pulmonology
Frankfurt
Hessen
Germany
60590

Status

Completed

Source

Johann Wolfgang Goethe University Hospitals

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:35:47-0400

Clinical Trials [662 Associated Clinical Trials listed on BioPortfolio]

Multicenter Trial of Immunotherapy With House Dust Mite Allergoid

Multicenter Immunotherapy House Dust Mite Allergoid

Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.

The Effect of Autologous Autovaccine in Patients With Allergy on House-Dust-Mite

House dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. We test a possibility to immunize subjects sensitized against house dust m...

Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house d...

PubMed Articles [9336 Associated PubMed Articles listed on BioPortfolio]

Intradermal immunotherapy with low-dose house dust mite allergens in patients with allergic rhinitis: A proof-of-concept study.

High-dose aqueous subcutaneous immunotherapy is a validated and effective administration route for house dust mite and pollen allergens.

Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared to molecular ImmunoCAPs.

We identified 6 house dust mite (HDM) allergen molecules to comprising the majority of HDM IgE-binding components and show that molecular ImmunoCAPs based on these six allergens are superior to allerg...

Newly designed hemagglutinin-Der p 2 chimera is a potential candidate for allergen specific immunotherapy.

Aim To investigate the immunomodulatory potential of a chimera composed of the receptor-binding domain of hemagglutinin 1 (H1s) from Influenza virus and Der p 2 (D2) allergen for allergen-specific imm...

Randomised controlled trials define shape of dose-response for Pollinex Quattro Birch allergoid immunotherapy.

The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX Quattro Plus 1.0 ml Birch 100%) is an effective, well-tolerated short course subcutaneous immunotherapy. We performed two phas...

Sublingual immunotherapy for treating adult patients with allergic rhinitis induced by house dust mite among Chinese Han population: A retrospective study.

The objective of this retrospective study was to evaluate the efficacy and safety of sublingual immunotherapy (SLIT) for treating adult patients with allergic rhinitis (AR) induced by house dust mite ...

Medical and Biotech [MESH] Definitions

Species of European house dust mite, in the family PYROGLYPHIDAE. It is the most commonly found house dust mite.

Species of American house dust mite, in the family PYROGLYPHIDAE.

Antigens from the house dust mites (DERMATOPHAGOIDES), mainly D. farinae and D. pteronyssinus. They are proteins, found in mite feces or mite extracts, that can cause ASTHMA and other allergic diseases such as perennial rhinitis (RHINITIS, ALLERGIC, PERENNIAL) and atopic dermatitis (DERMATITIS, ATOPIC). More than 11 groups of Dermatophagoides ALLERGENS have been defined. Group I allergens, such as Der f I and Der p I from the above two species, are among the strongest mite immunogens in humans.

Earth or other matter in fine, dry particles. (Random House Unabridged Dictionary, 2d ed)

Family of house dust mites, in the superfamily Analgoidea, order Astigmata. They include the genera Dermatophagoides and Euroglyphus.

More From BioPortfolio on "Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


Searches Linking to this Trial